Trulicity ® (dulaglutide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Trulicity Summary of Product Characteristics (SmPC)

How can I switch a patient to Trulicity® (dulaglutide) from another GLP-1 Receptor Agonist?

Eli Lilly and Company did not study the effects of switching from another GLP-1 RA to dulaglutide.

UK_cFAQ_GLP013_SWITCHING_FROM_ANOTHER_GLP-1_RA
UK_cFAQ_GLP013_SWITCHING_FROM_ANOTHER_GLP-1_RA
en-GB

Indication according to the label

Dulaglutide is a Glucagon-like peptide-1 receptor agonist (GLP-1 RA) indicated for once weekly dosing as an adjunct to diet and exercise for the treatment of adults with insufficiently controlled Type 2 Diabetes mellitus.1

What should I consider when switching?

As a physicians, you should follow your clinical judgment, taking into account the patient’s glycemic control, when deciding how to switch from one GLP-1 RA to another one. 

When transitioning a patient from another GLP-1 RA to dulaglutide, you should consider the prescribing information of the applicable GLP-1 RA and it's pharmacokinetic profile, including

  • onset of action
  • duration of action
  • half-life
  • time to steady state, and 
  • missing dosing information.

Please find the mentioned pharmacokinetic properties for dulaglutide in Pharmacokinetic properties of dulaglutide

Pharmacokinetic properties of dulaglutide 1,2

Onset of action

Improvement in glycemic control starts after the first administration

Duration of action

Improvement in glycemic control is sustained throughout the once-weekly dosing interval

Half-life

Approximately 5 days

Time to steady state

Steady state concentrations are achieved within 2 to 4 weeks.

Missing dosing information

Once steady state is achieved, missing 2 or more consecutive doses may result in subtherapeutic dulaglutide concentrations.

References

1Trulicity [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Date of Last Review: May 26, 2021


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request